Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
New site-agnostic therapies highlight the importance of genetic testing.
FDA approves Rozlytrek for cancers with certain gene mutations
New site-agnostic therapy shrank tumors in people with a variety of cancers with NTRK gene fusions as well as ROS1-positive lung cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.